Drug Policy > Psychedelic Substances

Tracking since May 19, 2026 · Latest signal Apr 20, 2026 · 6 matched data points

Overall sentiment

Positive 67% (4)Negative 0% (0)Neutral 33% (2)

Daily sentiment

Claims (2)

Claims contributing to this aggregate. Confirmed negative claims count as negative impact; confirmed positive claims count as positive impact.

President Trump has directed his administration to accelerate the review process for certain psychedelic substances.

Parent: Drug PolicyEntity: Psychedelic SubstancesImpact: positiveDate: Apr 18, 2026 - Apr 19, 2026Target: President Trump's directive to expedite the review of psychedelic substances4 matched entries4 confirmed0 disputed0 neutral0 unclear

Donald Trump's executive order aims to increase the accessibility of certain psychedelic substances for therapeutic use.

Parent: Drug PolicyEntity: Psychedelic SubstancesImpact: positiveDate: Apr 19, 2026 - Apr 20, 2026Target: Donald Trump's executive order to increase the accessibility of certain psychedelic substances for therapeutic use.2 matched entries0 confirmed0 disputed2 neutral0 unclear